Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

v2.4.1.9
Commitments and Contingencies - Additional Information (Detail) (USD $)
3 Months Ended
Mar. 31, 2015
UFRF License Agreements [Member]  
Commitment And Contingencies [Line Items]  
Company's obligation to pay from percentage of selling price of product 5.00%ogen_RoyaltyPaymentPercentage
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
Company's obligation to pay from all revenue received from sublicenses 22.00%ogen_RoyaltyPaymentPercentageSublicenses
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
One-time commercialization fee monthly amount for calculation $ 5,000ogen_MonthlyCalculationOfCommercializationFee
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
Post-commercialization minimum royalty payments 50,000ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
One-time additional royalty payment would be due when total cumulative royalties paid to UFRF exceed amount 2,000,000ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
One-time additional payment to UFRF as a percentage of total royalties due to UFRF 10.00%ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
Minimum annual maintenance payment per license agreement 10,000ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
Aggregate minimum annual maintenance payment 20,000ogen_AggregateMinimumAnnualMaintenancePayment
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
Quarterly maintenance payment to UFRF under installment plan 5,000ogen_MinimumQuarterlyMaintenancePayment
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
Texas A and M University License [Member]  
Commitment And Contingencies [Line Items]  
Company's obligation to pay from percentage of selling price of product 5.00%ogen_RoyaltyPaymentPercentage
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
Post-commercialization minimum royalty payments 100,000ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
Initial payment to Texas A&M 5,000ogen_InitialPaymentForLicensingAgreement
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
Minimum consideration for the continuation of the license agreement 15,000ogen_MinimumConsiderationForContinuationOfLicenseAgreement
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
Annual maintenance payment under licensing agreement with Texas A&M 100,000ogen_AnnualMaintenancePaymentUnderLicensingAgreement
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
Maximum period to cure the breach 60 days
Texas A and M University License [Member] | Phase I Clinical Trial [Member]  
Commitment And Contingencies [Line Items]  
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2015
Milestone payment under licensing agreement 50,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_PhaseOneClinicalTrialMember
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
Texas A and M University License [Member] | Phase II Clinical Trial [Member]  
Commitment And Contingencies [Line Items]  
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2019
Milestone payment under licensing agreement 100,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_PhaseTwoClinicalTrialMember
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
Texas A and M University License [Member] | Phase III Clinical Trial [Member]  
Commitment And Contingencies [Line Items]  
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2022
Milestone payment under licensing agreement 150,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_PhaseThreeClinicalTrialMember
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
Texas A and M University License [Member] | Sale Of Licensed Technology [Member]  
Commitment And Contingencies [Line Items]  
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2025
Milestone payment under licensing agreement 400,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_SaleOfLicensedTechnologyMember
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
Texas A and M University License [Member] | Minimum [Member]  
Commitment And Contingencies [Line Items]  
Company's obligation to pay from percentage of selling price of product 2.00%ogen_RoyaltyPaymentPercentage
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
Lantibiotic ECC [Member]  
Commitment And Contingencies [Line Items]  
Company's obligation to pay from percentage of selling price of product 25.00%ogen_RoyaltyPaymentPercentage
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
Company's obligation to pay from all revenue received from sublicenses 50.00%ogen_RoyaltyPaymentPercentageSublicenses
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
Number of shares issued 4,392,425us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
Maximum percentage of primary investment securities to investment of shares issued 10.00%ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
Number of milestones achieved 0ogen_NumberOfMilestonesAchieved
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
Termination notice period 90 days
Lantibiotic ECC [Member] | Investigational New Drug Application [Member]  
Commitment And Contingencies [Line Items]  
Percentage of number of shares of common stock equal to Base Shares 1.00%ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock
/ us-gaap_ProductOrServiceAxis
= ogen_InvestigationalNewDrugApplicationMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
Lantibiotic ECC [Member] | Clinical Study Phase 2 [Member]  
Commitment And Contingencies [Line Items]  
Percentage of number of shares of common stock equal to Base Shares 1.50%ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock
/ us-gaap_ProductOrServiceAxis
= ogen_ClinicalStudyPhaseTwoMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
Lantibiotic ECC [Member] | Clinical Study Phase 3 [Member]  
Commitment And Contingencies [Line Items]  
Percentage of number of shares of common stock equal to Base Shares 2.00%ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock
/ us-gaap_ProductOrServiceAxis
= ogen_ClinicalStudyPhaseThreeMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
Lantibiotic ECC [Member] | Filing of First Investigational New Drug Application [Member]  
Commitment And Contingencies [Line Items]  
Percentage of number of shares of common stock equal to Base Shares 2.50%ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock
/ us-gaap_ProductOrServiceAxis
= ogen_FilingOfFirstInvestigationalNewDrugApplicationMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
Lantibiotic ECC [Member] | First Regulatory Approval of Oragenics Product [Member]  
Commitment And Contingencies [Line Items]  
Percentage of number of shares of common stock equal to Base Shares 3.00%ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock
/ us-gaap_ProductOrServiceAxis
= ogen_FirstRegulatoryApprovalOfOragenicsProductMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
LBPs ECC [Member]  
Commitment And Contingencies [Line Items]  
Company's obligation to pay from percentage of selling price of product 10.00%ogen_RoyaltyPaymentPercentage
/ us-gaap_TypeOfArrangementAxis
= ogen_LiveBiotherapeuticProductsExclusiveChannelCollaborationMember
Maximum period to cure the breach 60 days
Number of milestones achieved 0ogen_NumberOfMilestonesAchieved
/ us-gaap_TypeOfArrangementAxis
= ogen_LiveBiotherapeuticProductsExclusiveChannelCollaborationMember
LBPs ECC [Member] | Phase II Clinical Trial [Member]  
Commitment And Contingencies [Line Items]  
Milestone payment under licensing agreement 2,000,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_PhaseTwoClinicalTrialMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LiveBiotherapeuticProductsExclusiveChannelCollaborationMember
Milestone measurement period 30 days
LBPs ECC [Member] | Phase III Clinical Trial [Member]  
Commitment And Contingencies [Line Items]  
Milestone payment under licensing agreement 5,000,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_PhaseThreeClinicalTrialMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LiveBiotherapeuticProductsExclusiveChannelCollaborationMember
Milestone measurement period 30 days
LBPs ECC [Member] | Sale Of Licensed Technology [Member]  
Commitment And Contingencies [Line Items]  
Milestone payment under licensing agreement $ 10,000,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_SaleOfLicensedTechnologyMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LiveBiotherapeuticProductsExclusiveChannelCollaborationMember
Milestone measurement period 30 days